All of the securities to be sold in the offering are being offered by 89bio. 89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of ...

Efruxifermin, also known as EFX, belongs to a class of drugs known as FGF21 analogs, which also includes 89bio's (NASDAQ:ETNB) MASH drug candidate, pegozafermin. 89bio's (ETNB) pegozafermin is ...

89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of pegozafermin, manufacturing related costs and other general corporate ...

The company is conducting trials with its experimental drug pegozafermin in patients with severe scarring of the liver. In patients who were not taking GLP-1s, 45% of those who were on Akero's ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG). The study ...

The firm's confidence in the biopharmaceutical company's prospects is tied to the progress of its Phase 3 ENTRUST study of pegozafermin, a treatment for severe hypertriglyceridemia (SHTG).

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase III drugs for Liver Cirrhosis have a 44% phase transition success ...

Pegozafermin is under clinical development by 89Bio and currently in Phase III for Fibrosis. According to GlobalData, Phase III drugs for Fibrosis does not have sufficient historical data to build an ...

该公司对这家生物制药公司前景的信心与其pegozafermin治疗严重高甘油三酯血症(SHTG)的III期ENTRUST研究进展密切相关。该研究已成功完成患者招募，预计将在2025年下半年公布顶线数据。 ENTRUST试验是一项全球III期试验，旨在评估pegozafermin在最多360名SHTG患者中的疗效。